Pacira BioSciences reports fourth-quarter, full-year 2021 financial results
Click Here to Manage Email Alerts
Pacira BioSciences Inc. has reported increased revenue and net product sales during the fourth-quarter and full-year 2021, leaving the company in the “strongest financial position” in company history, according to a press release.
Pacira reported a total revenue of $541.5 million in 2021, a 26% increase compared with the $429.6 million reported in 2020. The company also reported a total revenue of $159.2 million in the fourth quarter of 2021, a 22% increase compared with the prior year period.
“The acquisition of Flexion Therapeutics combined with record Exparel sales resulted in a pivotal year for Pacira, allowing us to enter 2022 in the strongest financial position in our company’s history,” David Stack, chair and CEO of Pacira, said in the release. “Despite challenges in the marketplace due to COVID-19, we continue to deliver strong results and remain bullish in our long-term expectations for growth.”
Read more about
Click Here to Manage Email Alerts